Tisotumab Vedotin Summary Slide Final_DOI.pdf (684.82 kB)
Download file

Tisotumab vedotin-tftv in previously treated recurrent or metastatic cervical cancer: a profile of its use in the USA

Download (684.82 kB)
online resource
posted on 30.08.2022, 21:09 authored by Esther S. Kim, Zaina T. Al-Salama

  

Declarations


Funding The preparation of this review was not supported by any external funding.


Authorship and Conflict of interest E. S. Kim, a contracted employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. Z. T. Al-Salama, a salaried employee of Adis International Ltd/Springer Nature and an editor of Drugs & Therapy Perspectives, was not involved in any publishing decisions for the manuscript and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.


Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.


  

Additional information about this Adis Drug Review can be found here


  

Abstract 

 Tisotumab vedotin-tftv (TIVDAK®), a tissue factor-directed antibody-drug conjugate, is a valuable option for the treatment of adult patients with recurrent or metastatic cervical cancer experiencing disease progression on or after chemotherapy in the USA. In a clinical trial in patients with previously treated recurrent or metastatic cervical cancer, treatment with tisotumab vedotin-tftv intravenous infusion led to clinically meaningful and durable antitumor activity. The tolerability profile of tisotumab vedotin-tftv was manageable, with most adverse events being mild or moderate in severity. The most frequently reported treatment-related adverse events included certain unique toxicities (e.g. ocular toxicity, hemorrhage), in addition to toxicities more common among patients receiving chemotherapy (e.g. alopecia, nausea, fatigue, anemia, peripheral neuropathy). Adherence to premedication and required eye care before, during, and after the infusion is essential. 


  

© Springer Nature Switzerland AG 2022


History